Top Insider Trades 11/6/13: Puma Biotech PBYI, USAK, RT, CCXI | Wealth Management
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotech plunges on drug side effects
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Puma Biotechnology
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Puma Biotechnology NPS & Customer Reviews | Comparably
Puma Biotechnology
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology Surging
Puma Biotechnology, Inc.
PumaBiotech (@pumabiotech) / Twitter
Puma Biotechnology Inc (PBYI) Stock Price & Performance 2023
Puma Biotechnology
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
Puma Biotechnology Inc
Henry Kuo - Head of Information Technology - Puma Biotechnology, Inc. | LinkedIn
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Exhibitor Puma Biotechnology 07-10 - Scripps CME Connection
PumaBiotech (@pumabiotech) / Twitter
